Core Viewpoint - The company, Zhejiang Shouxiangu Pharmaceutical Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented [2][3]. Financial Data Summary - The third-quarter financial statements have not been audited [3]. - The report includes major accounting data and financial indicators, with the reporting period defined as the three months from the beginning to the end of the quarter [3]. - A retrospective adjustment has been made due to a business combination with a subsidiary, impacting the financial data for the previous year [4]. Non-Recurring Gains and Losses - The company has identified significant non-recurring gains and losses, which are detailed in the report [5]. Shareholder Information - The report includes information on the total number of ordinary shareholders and the top ten shareholders, although there are no changes reported in the shareholding structure due to securities lending activities [7]. Financial Statements - The consolidated balance sheet and profit and loss statement for the period from January to September 2025 have been prepared, with the audit type noted as unaudited [9]. - The net profit of the acquired entity prior to the merger was reported as 63,703.61 yuan, while the previous year's net profit was -701,132.81 yuan [9].

Core Viewpoint - Shouxiangu (603896.SH) reported a decline in both revenue and net profit for the first three quarters of the year, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters was 430 million yuan, a year-on-year decrease of 10.23% [1] - The net profit attributable to shareholders was 76.34 million yuan, down 33.47% year-on-year [1] - The net profit excluding non-recurring gains and losses was 42.29 million yuan, reflecting a significant decline of 54.48% year-on-year [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥130,454,533.70, representing an increase of 8.51% compared to ¥119,452,348.03 in the same period last year[4] - The total profit for Q3 2025 decreased by 30.32% to ¥10,718,962.04 from ¥17,734,027.88 in the previous year[4] - The net profit attributable to shareholders for Q3 2025 was ¥10,783,105.44, down 30.15% from ¥17,797,076.96 year-on-year[4] - The basic earnings per share for Q3 2025 was ¥0.06, a decrease of 25.00% from ¥0.09 in the previous year[4] - Total operating revenue for the first three quarters of 2025 was CNY 430,138,219.40, a decrease of 10.23% compared to CNY 479,159,858.20 in the same period of 2024[18] - Operating profit for the first three quarters of 2025 was CNY 76,143,011.62, down 33.8% from CNY 114,914,017.94 in the first three quarters of 2024[19] - Net profit for the first three quarters of 2025 was CNY 76,346,218.54, a decline of 33.5% compared to CNY 114,746,646.06 in the same period of 2024[19] - Basic and diluted earnings per share for the first three quarters of 2025 were CNY 0.39, down from CNY 0.58 in the first three quarters of 2024[20] - The company reported a total comprehensive income of CNY 77,292,555.07 for the first three quarters of 2025, down from CNY 133,979,766.79 in the same period of 2024[19] Cash Flow - The net cash flow from operating activities increased by 51.24% to ¥20,940,482.65 compared to ¥14,339,593.21 in the same quarter last year[4] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 516,959,357.49, a decrease of 6.2% compared to CNY 551,162,261.17 in the same period of 2024[21] - The net cash flow from operating activities remained stable at CNY 143,934,561.17, slightly up from CNY 143,020,961.88 year-on-year[21] - Cash inflow from investment activities was CNY 508,582,834.33, down 61.4% from CNY 1,317,521,596.31 in the previous year[22] - The net cash flow from investment activities was negative at CNY -248,258,120.35, compared to a positive CNY 219,995,039.05 in the same period last year[22] - Cash inflow from financing activities totaled CNY 338,161,710.00, a decrease of 14.2% from CNY 393,983,609.10 in 2024[22] - The net cash flow from financing activities was negative at CNY -69,273,180.35, improving from CNY -244,724,725.20 in the previous year[22] - The total cash and cash equivalents at the end of the period decreased to CNY 133,160,363.81 from CNY 694,537,534.64 a year earlier, reflecting a significant decline of 80.9%[22] - The company received CNY 505,000,000.00 from investment recoveries, down from CNY 1,090,700,000.00 in the previous year, indicating a 53.7% decrease[21] - The cash paid for purchasing fixed assets and other long-term assets was CNY 207,297,228.65, a reduction of 55.3% compared to CNY 463,526,557.26 in the same period of 2024[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,154,624,430.70, reflecting a slight increase of 0.73% from ¥3,131,185,579.81 at the end of the previous year[5] - The company's total assets as of September 30, 2025, amount to ¥3,154,624,430.70, compared to ¥3,131,807,017.80 as of December 31, 2024[14] - Current assets total ¥1,436,703,862.13, a decrease from ¥1,520,659,727.33 in the previous year[14] - Total liabilities as of the reporting date were CNY 841,887,672.83, slightly up from CNY 840,519,671.65 in the previous period[16] - Total equity increased to CNY 2,312,736,757.87 from CNY 2,291,287,346.15, reflecting a growth of 0.93%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,715[11] - The largest shareholder, Zhejiang Shouxian Valley Investment Management Co., Ltd., holds 56,711,239 shares, accounting for 28.61% of total shares[12] Research and Development - The company reported a significant increase in research and development expenses by 32.32% due to increased investment in R&D[9] - Research and development expenses for the first three quarters of 2025 were CNY 42,091,658.84, an increase of 32.2% compared to CNY 31,810,538.64 in the same period of 2024[18] Other Financial Metrics - The weighted average return on equity decreased by 0.26 percentage points to 0.48% in Q3 2025 from 0.83% in the same period last year[4] - The company experienced a 54.48% decrease in net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date period[9] - The company completed the acquisition of 100% equity in Hangzhou Shouxian Valley Health Pharmacy Chain Co., Ltd., which constitutes a business combination under common control[5] - Sales expenses decreased to CNY 184,212,580.12 from CNY 215,945,990.95, a reduction of 14.7%[18] - Other income for the first three quarters of 2025 was CNY 35,722,954.55, an increase from CNY 20,381,829.94 in the same period of 2024[18] - The company did not apply new accounting standards for the current year, maintaining consistency in financial reporting[23]

Core Insights - The company Shouxiangu (603896.SH) reported a revenue of 430 million yuan for the first three quarters of 2025, representing a year-on-year decline of 10.23% [1] - The net profit attributable to the parent company was 76.34 million yuan, down 33.47% year-on-year [1] - The net profit after deducting non-recurring items was 42.29 million yuan, reflecting a significant decrease of 54.48% year-on-year [1] - The basic earnings per share stood at 0.39 yuan [1]

Core Insights - The article highlights the increasing trend of A-share listed companies in China engaging in physical rewards for shareholders, enhancing investor relations and creating a unique investment-consumption ecosystem [1][4]. Group 1: Company Activities - Over 30 listed companies have participated in shareholder reward activities since 2025, offering products, discount coupons, and tourism rights to investors [1][4]. - Companies like Tianyu Bio, Huasheng Co., and Beiqing Song have announced various forms of physical rewards, aiming to deepen shareholder experience with core products and strengthen their value recognition [2][3]. - The second "Listed Company Shareholder Festival" organized by Tonghuashun attracted nearly 100 companies, providing a wide range of gifts including electronics, food, and cosmetics to shareholders [3]. Group 2: Policy and Market Trends - The trend of physical rewards aligns with the China Securities Regulatory Commission's policy to enhance investor protection and improve returns for shareholders [4]. - The increasing participation of companies in physical reward activities indicates a shift from individual cases to a systematic approach in investor relations management [4]. - The practice of physical rewards is expected to become a significant indicator of corporate governance and market competitiveness in the future [4].

Core Viewpoint - The company, Zhejiang Shouxiangu Pharmaceutical Co., Ltd., has completed the registration change and amendment of its articles of association following the approval of its board and supervisory meetings [1] Group 1 - The company held its fifth board and supervisory meetings on August 27, 2025, where it approved the proposal to change its registered capital and cancel the supervisory board [1] - The proposal was subsequently approved at the first extraordinary general meeting of shareholders held on September 18, 2025 [1] - The company has completed the business registration change and obtained a new business license from the Zhejiang Provincial Market Supervision Administration [1]

浙江寿仙谷医药股份有限公司 章 程 二〇二五年九月（修订） | 第一章 | 总则 1 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 2 | | | 第三章 | 股份 3 | | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东会 6 | | | 第一节 | 股东的一般规定 | 6 | | 第二节 | 控股股东和实际控制人 | 10 | | 第三节 | 股东会的一般规定 | 11 | | 第四节 | 股东会的召集 | 14 | | 第五节 | 股东会的提案与通知 | 15 | | 第六节 | 股东会的召开 | 17 | | 第七节 | 股东会的表决和决议 | 20 | | 第五章 | 董事和董事会 24 | | | 第一节 | 董事的一般规定 | 24 | | 第二节 | 董事会 | 28 | | 第三节 | 独立董事 | 32 | | 第四节 | 董事会专门委员会 | 35 | | 第六章 | 高级管理人员 37 | | | 第七章 | 财务会计制度、利润分配和审计 39 | | ...

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-066 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 | 转债 22 | | 浙江寿仙谷医药股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、基本情况介绍 浙江寿仙谷医药股份有限公司（以下简称"公司"或"寿仙谷"）于 2025 年 8 月 27 日召开第五届董事会第二次会议和第五届监事会第二次会议，审议通 过了《关于变更公司注册资本、取消监事会暨修订<公司章程>的议案》，具体内 容详见公司于 2025 年 8 月 28 日披露的《寿仙谷关于变更公司注册资本、取消监 事会暨修订<公司章程>及废止、修订和制定部分治理制度的公告》（公告编号： 2025-055）。该事项已经公司于 2025 年 9 月 18 日召开的 2025 年第一次临时股东 大会审议通过，并授权公司管理层及相关人员办理工商变更登记、章程备案等相 关事宜。 | 法定代表人： | 李明焱 | ...

Core Insights - Traditional Chinese medicine company Shouxiangu (603896) is diversifying into fast-moving consumer goods (FMCG) due to performance challenges, hiring former Wahaha sales manager Shen Jiangang to oversee operations [1][2] - The company has established a multi-category matrix for food and medicine integration, launching products like Dendrobium juice and Shouxiangu porridge, with all FMCG operations managed by its subsidiary [1][2] Financial Performance - Since its listing in May 2017, Shouxiangu's revenue grew continuously for six years, peaking at 829 million yuan in 2022, but saw a 5.39% decline in 2023 to 784 million yuan, with a further 11.81% drop projected for 2024 [2] - The company's net profit followed a similar trend, experiencing an 8.39% decline in 2023 and a projected 31.34% drop in 2024 [2] Recent Quarterly Results - In the first half of 2023, Shouxiangu reported total revenue of 300 million yuan, down 16.51% year-on-year, and a net profit of approximately 65.56 million yuan, down 33.99% [5] - The second quarter showed improvement with revenue of 129 million yuan, a decline of 6.64%, compared to a 22.68% drop in the first quarter, with July showing positive growth [5] Product Performance - In the first half of 2023, revenue from Ganoderma lucidum spore products was 216 million yuan, accounting for 73.11% of total revenue, down 17.79% year-on-year [5] - Revenue from Dendrobium products was 46.66 million yuan, representing 15.83% of total revenue, down 24.25% [6] Strategic Direction - Shouxiangu aims to maintain its focus on high-end products like third-generation broken-wall Ganoderma lucidum spore powder while considering a mix of high, medium, and low-tier products for different channels [7] - The company acknowledges the current market challenges and emphasizes the importance of effectively reaching consumers to capitalize on untapped market potential [8]

Group 1 - The board of directors of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. held its fourth meeting of the fifth session on October 14, 2025, with all nine directors present, confirming compliance with relevant laws and regulations [1] - The board approved the election of Li Mingyan as the executive director and legal representative of the company, with a term lasting until the end of the fifth board session, with a unanimous vote of 9 in favor [1] - The board confirmed the members and convener of the audit committee, which will now assume the responsibilities previously held by the supervisory board, with Jin Ying as the convener, also serving until the end of the fifth board session [1]